STPE VOIDS

8-22-62 Stabolog Seg

PTO/SB/21 (08-00)
Approved for use through 10/31/2002. OMB 0651-0031
U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE
URLANGE Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it displays a valid OMB control number.

		Application Number	09/631,152
TRANSMITTAL		Filing Date	08/02/2000
FORM		First Named Inventor	Jon Wolff
(to be used for all correspondence after initial filing)		Group Art Unit	1636
		Examiner Name	
Total Number of Pages in This Submissio	on 7	Attorney Docket Number	Mirus.017.01
<u> </u>	ENCL	OSURES (check a	all that apply)
Fee Transmittal Form Fee Attached Amendment / Reply After Final Affidavits/declaration(s) Extension of Time Request Express Abandonment Request Information Disclosure Statement Certified Copy of Priority Document(s) Response to Missing Parts/ Incomplete Application Response to Missing Parts under 37 CFR 1.52 or 1.53	(for an A	tent Papers (pplication) (s) g-related Papers to Convert to a nal Application of Attorney, Revocation of Correspondence I Disclaimer t for Refund	After Allowance Communication to Group Appeal Communication to Board of Appeals and Interferences Appeal Communication to Group (Appeal Notice, Brief, Reply Brief) Proprietary Information Status Letter Other Enclosure(s) (please identify below): Replacement pages 3.5" disk containing Seq. Listing Paper version of Seq. Listing RECEIVED AUG 2 6 2002
SIGNATURE	OE APPLI	CANT, ATTORNEY, OR A	GENT TECH CENTER TO DO 200
Firm or Individual name Signature Mirus Corporation	*		NOLINI (ILC.)
Date	_	08/16/2002	

CERTIFICATE OF MAILING

I hereby certify that this correspondence is being deposited with the United States Postal Service with sufficient postage as first class mail in an envelope addressed to: Commissioner for Patents, Washington, DC 20231 on this date:

August 16, 2002

Typed or printed name

Mark K. Johnson

EN 52558332 NZ

Signature

V Johnson

Date

08/16/2002

Burden Hour Statement: This form is estimated to take 0.2 purs to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORM TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, DC 20231.



UNITED STATES DEPARTMENT OF COMMERCE
Patent and Trad mark Offic

COMMISSIONER OF PATENTS AND TRADEMARKS Washington, D.C. 20231

SERIAL NUMBER	FILING DATE	FIRST NAMED APPLICANT	ATTORNEY DOCKET NO.
09/631,152	08/02/2000	Wolff et al.	Mirus.017.01

RECEIVED

AUG 2 6 2002

TECH CENTER 1600/2900

EXAMINER				
Sita S. Pappu				
ART UNIT	PAPER NUMBER			
1636	. 8			

Please find below a communication from the EXAMINER in charge of this application

This application contains sequence disclosures that are encompassed by the definitions for nucleotide and/or amino acid sequences set forth in 37 C.F.R. § 1.821(a)(1) and (a)(2). However, this application fails to comply with the requirements of 37 C.F.R. §§ 1.821-1.825 for the reason(s) set forth on the attached Notice To Comply With Requirements For Patent Applications Containing Nucleotide Sequence And/Or Amino Acid Sequence Disclosures. Applicant must comply with the requirements of the sequence rules (37 CFR 1.821-1.825) before the application can be examined under 35 U.S.C. §§ 131 and 132.

The computer readable form that has been filed with this application has been found to be damaged and/or unreadable as indicated in the attached CRF diskette problem report. A substitute computer readable form must be submitted as required by 37 C.F.R. 1.825(d) along with a substitute paper copy and a statement that the content of the paper and computer redable copies are the same and, where applicable, include no new matter, as required by 37 C.F.R. 1.821(e) or 1.821(f) or 1.821(g) or 1.825(b) or 1.825(d).

APPLICANT IS GIVEN 30 days FROM THE DATE OF THIS LETTER WITHIN WHICH TO COMPLY WITH THE SEQUENCE RULES, 37 C.R.F. §§ 1.821-1.825. Failure to comply with these requirements will result in ABANDONMENT of the application under 37 C.F.R. § 1.821(g). Extensions of time may be obtained by filing a petition accompanied by the extension fee under the provisions of 37 C.F.R. § 1.136. In no case may an applicant extend the period for response beyond the six month statutory period. Direct the response to the undersigned. Applicant is requested to return a copy of the attached Notice to Comply with the response.

Any inquiry concerning this communication or earlier communications from the examiner should be directed to Examiner Sita S. Pappu whose telephone number is (703) 305-5039. If the examiner cannot be reached, inquiries can be directed to Supervisory Patent Examiner Irem Yucel whose telephone number is (703) 305-1998. The fax number for the organization where this application is assigned is (703) 308-8724. Any inquiry of a general nature or relating to the status of this application should be directed to the Patent Analyst at (703) 305-2982.

Anne-Marie Baken ANNE-MARIE BAKER PATENT EXAMINER

Application	:	09/631152
-------------	---	-----------

NOTICE TO COMPLY WITH REQUIREMENTS FOR PATENT APPLICATIONS CONTAINING NUCLEOTIDE SEQUENCE AND/OR AMINO ACID SEQUENCE DISCLOSURES

Applicant must file the items indicated below within the time period set the Office action to which th Notice is attached to avoid abandonment under 35 U.S.C. § 133 (extensions of time may be obtained under the provisions of 37 CFR 1.136(a)).

The nucleotide and/or amino acid sequence disclosure contained in this application does not comp with the requirements for such a disclosure as set forth in 37 C.F.R. 1.821 - 1.825 for the following reason(s):

	•	
AUG 1 9 2002 B	1. This application clearly fails to comply with the requirements of 37 C.F.R. 1.821-1.825 attention is directed to the final rulemaking notice published at 55 FR 18230 (May 1, 10 OG 29 (May 15, 1990). If the effective filing date is on or after July 1, 1998, see the notice published at 63 FR 29620 (June 1, 1998) and 1211 OG 82 (June 23, 1998).	1990), and 1114
CE MANDEMARKS TO	2. This application does not contain, as a separate part of the disclosure on paper copy Listing" as required by 37 C.F.R. 1.821(c).	, a "Sequence
	3. A copy of the "Sequence Listing" in computer readable form has not been submitted 37 C.F.R. 1.821(e).	as required by
	4. A copy of the "Sequence Listing" in computer readable form has been submitted. Ho content of the computer readable form does not comply with the requirements of 37 (and/or 1.823, as indicated on the attached copy of the marked -up "Raw Sequence Li	C.F.R. 1.822
	5. The computer readable form that has been filed with this application has been found and/or unreadable as indicated on the attached CRF Diskette Problem Report. A Su computer readable form must be submitted as required by 37 C.F.R. 1.825(d).	
	6. The paper copy of the "Sequence Listing" is not the same as the computer readable "Sequence Listing" as required by 37 C.F.R. 1.821(e).	from of the
	7. Other: Applicant Must Provide:	
\boxtimes	An initial or substitute computer readable form (CRF) copy of the "Sequence Listing".	
×	An initial or substitute paper copy of the "Sequence Listing", as well as an amendment of the specification.	directing its entry in
X	A statement that the content of the paper and computer readable copies are the same a applicable, include no new matter, as required by 37 C.F.R. 1.821(e) or 1.821(f) or 1.825(b) or 1.825(d).	
For	augstions regarding compliance to these requirements, please contact:	מביי ביי
For	Rules Interpretation, call (703) 308-4216 CRF Submission Help, call (703) 308-4212 Sentin Software Program Support	RECEIVED AUG 2 6 2002

PLEASE RETURN A COPY OF THIS NOTICE WITH YOUR REPLY

TECH CENTER 1600/2900

Technical Assistance......703-287-0200

To Purchase Patentin Software......703-306-2600